Connect Biopharma Holdings Limited Rightofuse Assets Revalued Assets At Cost
Connect Biopharma Holdings Limited (CNTB) had Rightofuse Assets Revalued Assets At Cost of $1.19 million as of 2024-06-30, per its 6-K filed 2024-09-05.
Discontinued › Notes
ifrs-full:RightofuseAssetsRevaluedAssetsAtCost · last filed 2024-09-05
- 2023-06-30: Rightofuse Assets Revalued Assets At Cost 8.32M CNY.
- 2022-12-31: Rightofuse Assets Revalued Assets At Cost 28.47M CNY.
- 2022-06-30: Rightofuse Assets Revalued Assets At Cost 28.34M CNY.
- 2021-12-31: Rightofuse Assets Revalued Assets At Cost 24.89M CNY.
CNY
| Period end | Rightofuse Assets Revalued Assets At Cost |
|---|---|
| 2023-06-30 | 8.32M CNY 6-K · filed 2023-09-12 |
| 2022-12-31 | 28.47M CNY 20-F · filed 2023-04-11 |
| 2022-06-30 | 28.34M CNY 6-K · filed 2022-09-13 |
| 2021-12-31 | 24.89M CNY 20-F · filed 2022-03-31 |
USD
| Period end | Rightofuse Assets Revalued Assets At Cost |
|---|---|
| 2024-06-30 | $1.19M 6-K · filed 2024-09-05 |
| 2023-12-31 | $1.19M 20-F · filed 2024-04-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Yarrow Bioscience, Inc. (YARW) | United States | $0.070B | |
| PLIANT THERAPEUTICS, INC. (PLRX) | United States | $0.071B | -0.76 |
| TENAX THERAPEUTICS, INC. (TENX) | United States | $0.071B | -7.17 |
| PMV Pharmaceuticals, Inc. (PMVP) | United States | $0.071B | -0.95 |
| Lunai Bioworks Inc. (LNAI) | United States | $0.072B | -0.11 |
| XBiotech Inc. (XBIT) | United States | $0.066B | -1.56 |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| HYPERION DEFI, INC. (HYPD) | United States | $0.065B | |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |